These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 19419279)

  • 1. Xience V everolimus-eluting coronary stent.
    Kukreja N; Onuma Y; Serruys PW
    Expert Rev Med Devices; 2009 May; 6(3):219-29. PubMed ID: 19419279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of the Xience V® everolimus-eluting coronary stent system.
    Claessen BE; Caixeta A; Henriques JP; Piek JJ
    Expert Rev Cardiovasc Ther; 2010 Oct; 8(10):1363-74. PubMed ID: 20936921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent.
    Beijk MA; Piek JJ
    Expert Rev Med Devices; 2007 Jan; 4(1):11-21. PubMed ID: 17187467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-eluting stents: clinical experiences and perspectives.
    Grube E; Gerckens U; Buellesfeld L
    Minerva Cardioangiol; 2002 Oct; 50(5):469-73. PubMed ID: 12384629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).
    Kereiakes DJ; Cutlip DE; Applegate RJ; Wang J; Yaqub M; Sood P; Su X; Su G; Farhat N; Rizvi A; Simonton CA; Sudhir K; Stone GW
    J Am Coll Cardiol; 2010 Dec; 56(25):2084-9. PubMed ID: 21144968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus.
    Stone GW; Kedhi E; Kereiakes DJ; Parise H; Fahy M; Serruys PW; Smits PC
    Circulation; 2011 Aug; 124(8):893-900. PubMed ID: 21824922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The paclitaxel-eluting stent in percutaneous coronary intervention: Part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions.
    Ray GM; Nawarskas JJ; Frishman WH
    Cardiol Rev; 2006; 14(3):143-50. PubMed ID: 16628023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of the XIENCE V everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice.
    Waksman R; Barbash IM; Dvir D; Torguson R; Ben-Dor I; Maluenda G; Xue Z; Satler LF; Suddath WO; Kent KM; Pichard AD
    Am J Cardiol; 2012 May; 109(9):1288-94. PubMed ID: 22341925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percutaneous coronary intervention with everolimus-eluting stents (Xience V): systematic review and direct-indirect comparison meta-analyses with paclitaxel-eluting stents (Taxus) and sirolimus-eluting stents (Cypher).
    Biondi-Zoccai G; Lotrionte M; Moretti C; Agostoni P; Sillano D; Laudito A; Sheiban I
    Minerva Cardioangiol; 2008 Feb; 56(1):55-65. PubMed ID: 18432169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of a randomized clinical comparison of everolimus-eluting (Xience v/Promus) and sirolimus-eluting (cypher select+) coronary stents in unselected patients with coronary heart disease.
    Jensen LO; Thayssen P; Tilsted HH; Ravkilde J; Junker A; Hansen HS; Hansen KN; Pedersen KE; Sørensen HT; Thuesen L; Lassen JF;
    Cardiology; 2010; 116(2):73-8. PubMed ID: 20523042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry.
    Onuma Y; Kukreja N; Piazza N; Eindhoven J; Girasis C; Schenkeveld L; van Domburg R; Serruys PW;
    J Am Coll Cardiol; 2009 Jul; 54(3):269-76. PubMed ID: 19589442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental efficacy of an everolimus eluting cobalt chromium stent.
    Carter AJ; Brodeur A; Collingwood R; Ross S; Gibson L; Wang CA; Haller S; Coleman L; Virmani R
    Catheter Cardiovasc Interv; 2006 Jul; 68(1):97-103. PubMed ID: 16755598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial).
    Smits PC; Kedhi E; Royaards KJ; Joesoef KS; Wassing J; Rademaker-Havinga TA; McFadden E
    J Am Coll Cardiol; 2011 Jun; 58(1):11-8. PubMed ID: 21514083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic sub-study in the SPIRIT III Randomized and Controlled Trial of XIENCE V everolimus eluting coronary stent system.
    Wang Q; Pierson W; Sood P; Bol C; Cannon L; Gordon P; Saucedo J; Sudhir K
    J Interv Cardiol; 2010 Feb; 23(1):26-32. PubMed ID: 20040005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular response to a third generation everolimus-eluting stent.
    Wilson GJ; Huibregtse BA; Stejskal EA; Crary J; Starzyk RM; Dawkins KD; Barry JJ
    EuroIntervention; 2010 Sep; 6(4):512-9. PubMed ID: 20884440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents in patients with coronary artery disease.
    Zhang F; Dong L; Qian J; Ge J
    Ann Med; 2011 Feb; 43(1):75-9. PubMed ID: 21171912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New-generation drug-eluting stents: focus on Xience V® everolimus-eluting stent and Resolute® zotarolimus-eluting stent.
    Van Dyck CJ; Hoymans VY; Haine S; Vrints CJ
    J Interv Cardiol; 2013 Jun; 26(3):278-86. PubMed ID: 23607275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial).
    Ng VG; Lansky AJ; Hermiller JB; Farhat N; Applegate RJ; Yaqub M; Sood P; Su X; Simonton CA; Sudhir K; Stone GW
    Am J Cardiol; 2011 Mar; 107(6):841-8. PubMed ID: 21255760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.